Poster Will Discuss Expanded and Improved Applications of Novel Pluripotent Stem-Based Screening System for Heart Toxicity SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/11/13 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue,

Companies Structure Collaboration to Focus on Development and Characterization of VistaGen's Human Pluripotent Stem-Cell Derived Liver Cells SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/04/13 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for

Latest Developments Enable Advanced Tools for Drug Rescue and Potential Cell Therapies Based on Human Definitive Hematopoietic Precursor Cells SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 02/07/13 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for

Lead Prodrug Candidate Is Being Developed for Chronic Neuropathic Pain SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 01/23/13 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism screening, today

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 01/22/13 -- VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism screening, today announced that Shawn K.

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 12/03/12 -- VistaGen Therapeutics, Inc. (OTCBB: VSTA), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism screening, has formalized its membership in the Toronto-based Centre for

Novel Human Stem Cell-Based Bioassay Based on VistaGen's Human Clinical Trials in a Test Tube(TM) Platform SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 11/13/12 -- VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue,

Company Also Completes Long-Term Debt Restructuring SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 09/06/12 -- VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue and novel pharmaceutical assays for predictive heart and liver

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 05/14/12 -- VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, today issued the following letter to its stockholders and the investment community from its CEO, Shawn Singh.

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 04/25/12 -- VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue, has secured a new United States patent covering the company's proprietary methods used to measure and type the toxic